|
|
|
Volumn 74, Issue 3, 2002, Pages 21-25
|
|
Clinicobiochemical aspects of flixotide administration in patients with moderate bronchial asthma
a a a a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA TOCOPHEROL;
ANDROSTANE DERIVATIVE;
ANTIINFLAMMATORY AGENT;
BETA 2 ADRENERGIC RECEPTOR;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
BRONCHODILATING AGENT;
CATALASE;
DRUG DERIVATIVE;
FLUTICASONE;
GLUTATHIONE REDUCTASE;
MALONALDEHYDE;
PHOSPHOLIPID;
SALBUTAMOL;
SALMETEROL;
SCHIFF BASE;
SUPEROXIDE DISMUTASE;
ADULT;
ARTICLE;
ASTHMA;
BLOOD;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DRUG COMBINATION;
DRUG EFFECT;
FEMALE;
HUMAN;
LIPID PEROXIDATION;
MALE;
METABOLISM;
MULTICENTER STUDY;
ADRENERGIC BETA-AGONISTS;
ADULT;
ALBUTEROL;
ALPHA-TOCOPHEROL;
ANDROSTADIENES;
ANTI-INFLAMMATORY AGENTS;
ASTHMA;
BRONCHODILATOR AGENTS;
CATALASE;
DRUG THERAPY, COMBINATION;
FEMALE;
GLUTATHIONE REDUCTASE;
HUMANS;
LIPID PEROXIDATION;
MALE;
MALONDIALDEHYDE;
PHOSPHOLIPIDS;
RECEPTORS, ADRENERGIC, BETA-2;
SCHIFF BASES;
SUPEROXIDE DISMUTASE;
|
|
EID: 0036366115
PISSN: 00403660
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (3)
|
|
References (5)
|
